WARNINGS AND PRECAUTIONS

• Long-term use of lamivudine 300 mg can trigger a resistant hepatitis B virus (YMDD) mutant.
• Use with caution for patients with impaired renal function and do not prescribe this treatment to patients with impaired hepatic function.
• Autoimmune disorders have been reported and symptoms can occur many months after initiation of antiretroviral therapy.
• Patients who are infected with HIV and HCV and are on both interferon and lamivudine can experience liver damage.
• HIV or HBV-infected women on lamivudine are warned to discontinue breastfeeding as this puts the baby at risk for HIV transmission and medication side effects.
• Do not prescribe lamivudine/zidovudine, abacavir/lamivudine, or abacavir/lamivudine/zidovudine to patients taking emtricitabine.
• Lamivir 150 mg  is contraindicated in patients with previous hypersensitivity reactions to lamivudine.
• The drug can trigger an inflammatory response to opportunistic infections such as Pneumocystis jirovecii, (MAC) Mycobacterium avium complex, cytomegalovirus (CMV), and M. tuberculosis.
• Are pregnant or having an intention to become pregnant. The consumption of Lamivudine while on pregnancy has not been associated with an increased risk of birth defects. Discuss with your doctor/healthcare provider if you want to become pregnant.
• Womens with this medication may be more likely to get serious liver problems or lactic acidosis, very overweight (obese), or have been taking nucleoside analog medicines for a long time.